Department of Physiology, São Paulo State University (Unesp), Institute of Biosciences, Botucatu, São Paulo 18618-970, Brazil.
Department of Pharmaceutical Sciences, Health Sciences Center, Federal University of Paraíba, João Pessoa, Paraíba 58051-900, Brazil.
Biomolecules. 2020 Feb 10;10(2):265. doi: 10.3390/biom10020265.
Peptic ulcer disease (PUD) is a multifactorial and complex disease caused by an imbalance of protective and aggressive factors (endogenous and exogenous). Despite advances in recent years, it is still responsible for substantial mortality and triggering clinical problems. Over the last decades, the understanding of PUD has changed a lot with the discovery of Helicobacter pylori infection. However, this disease continues to be a challenge due to side-effects, incidence of relapse from use of various anti-ulcer medicines, and the rapid appearance of antimicrobial resistance with current H. pylori therapies. Consequently, there is the need to identify more effective and safe anti-ulcer agents. The search for new therapies with natural products is a viable alternative and has been encouraged. The literature reports the importance of monoterpenes based on the extensive pharmacological action of this class, including wound healing and anti-ulcerogenic agents. In the present study, 20 monoterpenes with anti-ulcerogenic properties were evaluated by assessing recent in vitro and in vivo studies. Here, we review the anti-ulcer effects of monoterpenes against ulcerogenic factors such as ethanol, nonsteroidal anti-inflammatory drugs (NSAIDs), and Helicobacter pylori, highlighting challenges in the field.
消化性溃疡病(PUD)是一种由保护和侵袭因素(内源性和外源性)失衡引起的多因素和复杂疾病。尽管近年来取得了进展,但它仍然是导致大量死亡和引发临床问题的主要原因。在过去的几十年中,随着幽门螺杆菌感染的发现,人们对 PUD 的认识发生了很大变化。然而,由于各种抗溃疡药物的副作用、复发发生率以及当前幽门螺杆菌治疗中抗菌药物耐药性的快速出现,这种疾病仍然是一个挑战。因此,需要确定更有效和安全的抗溃疡药物。从天然产物中寻找新的治疗方法是一种可行的选择,并得到了鼓励。文献报道了单萜类化合物的重要性,这是基于此类化合物广泛的药理学作用,包括伤口愈合和抗溃疡作用。在本研究中,通过评估最近的体外和体内研究,评估了 20 种具有抗溃疡特性的单萜类化合物。在这里,我们综述了单萜类化合物对乙醇、非甾体抗炎药(NSAIDs)和幽门螺杆菌等溃疡形成因素的抗溃疡作用,强调了该领域的挑战。
Aliment Pharmacol Ther. 2009-5-1
Fundam Clin Pharmacol. 2004-2
Korean J Gastroenterol. 2016-6-25
Endocr Metab Immune Disord Drug Targets. 2023
Lancet. 2017-2-25
World J Gastroenterol. 2023-11-28
J Formos Med Assoc. 2010-1
Korean J Gastroenterol. 2012-5
Front Neurosci. 2025-7-10
Recent Adv Inflamm Allergy Drug Discov. 2024
Dig Dis. 2020-1-6
Helicobacter. 2019-9
Food Chem Toxicol. 2018-10-30
J Neurogastroenterol Motil. 2018-7-30
Lancet Gastroenterol Hepatol. 2018-2-21
Biomed Pharmacother. 2017-12-27
Acta Pharm Sin B. 2017-3
Lancet. 2017-2-25